Rafferty Asset Management LLC Sells 25,740 Shares of Exact Sciences Corporation $EXAS

Rafferty Asset Management LLC lessened its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 14.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,968 shares of the medical research company’s stock after selling 25,740 shares during the quarter. Rafferty Asset Management LLC owned approximately 0.08% of Exact Sciences worth $8,041,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new position in Exact Sciences during the 1st quarter valued at $604,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Exact Sciences by 11.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,186 shares of the medical research company’s stock valued at $921,000 after purchasing an additional 2,231 shares during the last quarter. Great Lakes Advisors LLC lifted its position in shares of Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after purchasing an additional 178 shares in the last quarter. Focus Partners Wealth boosted its holdings in Exact Sciences by 12.6% during the first quarter. Focus Partners Wealth now owns 21,548 shares of the medical research company’s stock worth $933,000 after purchasing an additional 2,413 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Exact Sciences by 0.9% during the second quarter. Envestnet Asset Management Inc. now owns 248,535 shares of the medical research company’s stock worth $13,207,000 after purchasing an additional 2,182 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on EXAS. Wolfe Research lowered shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Zacks Research cut Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Wall Street Zen downgraded Exact Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Benchmark cut Exact Sciences from a “buy” rating to a “hold” rating in a research note on Monday, November 24th. Twenty-one research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Exact Sciences presently has a consensus rating of “Reduce” and an average target price of $92.13.

Exact Sciences Stock Down 0.0%

Shares of NASDAQ EXAS opened at $103.35 on Tuesday. The business’s fifty day moving average price is $102.51 and its 200-day moving average price is $80.50. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $103.67. The stock has a market capitalization of $19.73 billion, a PE ratio of -93.95, a P/E/G ratio of 2.35 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. Exact Sciences’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.06) EPS. On average, equities research analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.